Physicians at Mayo Clinic's Individualized Medicine Clinic and researchers at the Translational Genomics Research Institute (TGen) have personalized drug treatments for patients
with cholangiocarcinoma using genomic sequencing technologies.
Not exact matches
A patients» tumors from
cholangiocarcinoma, a rare liver cancer that typically fails chemotherapy, shrunk significantly after treatment
with FGFR inhibitors, which were prescribed based on results of next generation sequencing.
«We now hope to design larger clinical studies to treat patients» tumors harboring these novel genomic aberrations to further explore the precise extent of clinical benefit for patients
with primary or advanced
cholangiocarcinoma.»
A team of current and former Mayo Clinic researchers has discovered that aspirin use is associated
with a significantly reduced risk of developing bile duct cancer, also called
cholangiocarcinoma.
A Phase 3, Multicenter, Randomized, Double - Blind, Placebo - Controlled Study of AG - 120 in Previously - Treated Subjects
with Nonresectable or Metastatic
Cholangiocarcinoma with an IDH1 Mutation
A Randomized Phase 2 Study of Atezolizumab in Combination
with Cobimetinib Versus Atezolizumab Monotherapy in Participants
with Unresectable
Cholangiocarcinoma
A Pivotal Trial of ARQ 087 in Subjects
with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic
Cholangiocarcinoma
An Open - Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B - 6527 in Subjects
with Advanced Hepatocellular Carcinoma or Intrahepatic
Cholangiocarcinoma
Incidences of intrahepatic
cholangiocarcinoma (ICC) are happening more often,
with patients facing low chances of surviving the disease using current treatments - this can be as low as five per cent survival rate 12 months after diagnosis.
Dr. Azad's clinical expertise is in cancers of the gastrointestinal tract,
with a concentration in colorectal cancer,
cholangiocarcinoma / pancreaticobiliary tract cancer.